Lumateperone

CHEMBL3306803 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

393.5 g/mol

LogP

3.8

Phase

4

An atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar disorder. It has a unique pharmacological profile acting simultaneously on dopamine, serotonin, and glutamate receptors.

Molekularmasse

393,5000 g/mol

LogP

3,80

TPSA

26,80 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Alzheimer's Disease Schizophrenia Bipolar Disorder Major Depressive Disorder

Wirkmechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12

InChI

InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1

Molecular Formula

C24H28FN3O

HBD / HBA

- / 5

Rotierbare Bindungen

5

Schwere Atome

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar disorder. It has a unique pharmacological profile acting simultaneously on dopamine, serotonin, and glutamate receptors.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Lumateperone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3306803. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 21302490. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Lumateperone auf PillFYI

Struktur

Schnelldaten

Formel: C24H28FN3O
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.